DGAP-News 222 0 Kommentare Celonic AG : Celonic to Boost its Cell & Gene Therapy Production with Facility in the upcoming Life Science Park Rheintal in Stein, Switzerland - Seite 2

The development and manufacturing capabilities of Celonic, together with the infrastructure of the Life Science Park Rheintal and the expertise of Europe's leading region for life sciences and pharmaceutical development, will establish the region of Basel and Stein as the central hub for the development and commercialization of next-generation ATMPs to support patients with unmet medical needs.

"We would like to warmly welcome Celonic as a new tenant to the new Life Science Park Rheintal in Stein, which offers a comprehensive portfolio of services and an excellent environment for life sciences companies. We look forward to creating an attractive life sciences hub that benefits from the excellent competitive situation in north-western Switzerland," says Javier Hernández, Head Global Site Development, Novartis Technical Operations.

Currently, the Life Science Park is home to more than 2,000 employees from three pharmaceutical and biotechnology companies working in research, development, and production.

fncls.ssp?fn=download2_file&code_str=6b5e4d574a3558f990603364af6cb3bc

Caption: New Cell & Gene Therapy Production Facility in the Life Science Park Rheintal in Stein, Switzerland

About Celonic
Celonic, a global CDMO (contract development & manufacturing organization) for innovative biopharmaceuticals, including cell and gene therapy products, is part of the private and independent family-owned company J.RETTENMAIER & Söhne (JRS-Group), with currently two production sites - in Basel, Switzerland (headquarters) and in Heidelberg, Germany. Founded more than 30 years ago, Celonic has continuously evolved from research projects on GMP manufacturing for clinical materials to commercial market supply. With more than 20 years of experience in GMP manufacturing, Celonic acts as an internationally acknowledged manufacturing partner.

For more information, visit www.celonic.com

Celonic Contact Details

Konstantin Matentzoglu
CEO
Celonic AG
Tel +41 61 564 9150

Soenke Brunswieck
VP Cell & Gene Therapy
Celonic AG
Tel +41 61 564 9150

25.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de